MARKET IS CLOSED
Loading latest tickers...

Market Indices

S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%

Sector Heatmap

Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%

CLYM — Climb Bio, Inc. Common Stock

Nasdaq

Climb Bio, Inc. Common Stock

CompareBack to Screener
$10.94
-0.13(-1.17%)
O
11.29
H
11.29
L
10.73
V
1.57M
⏱️ End-of-day dataAs of Oct 2, 2026
OverviewStatisticsFinancialsHistorical DataOptionsDividend HistoryNewsChart

Chart

About CLYM

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateAug 10, 2021
Employees29
Stock ExchangeNasdaq
Ticker SymbolCLYM
Websitehttps://www.climbbio.com

Key Financial Statistics

Market Cap$669.71M
P/E RatioN/A
Dividend YieldNone
EPSN/A
BetaN/A
52-Week Range$1.54 - $18.33
52-Week Avg Volume1.12M
VWAP$10.90
Transactions18,712
Total Recorded Bars506 days